Curated CRC research — accessible, accurate, actionable

The CRC Digest

Monday, August 31, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◆ TRIAL DATA

  Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer

  The prospective, randomized FIND trial used dynamic ctDNA methylation monitoring to personalize follow-up care after surgery in stage I-III patients. (Journal of Clinical Oncology)

• ▸ TREATMENT

  Immunotherapy produces durable responses in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status

  Patients with dMMR/MSI-H tumors who had poor performance status still achieved durable responses to immunotherapy, expanding treatment options for this vulnerable group. (Clinical Colorectal Cancer)

• ◇ RESEARCH

  NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis

  Preclinical research found that the NF-κB/LCN2 signaling pathway enhances cisplatin sensitivity in BRAF V600E-mutant CRC cells through iron-dependent cell death. (Cancers)

• ♥ LIVING WITH CRC

  Study evaluates potential hearing damage from oxaliplatin in preclinical model

  Mouse study evaluated potential hearing damage induced by oxaliplatin. (Hearing Research)

These findings continue to advance our understanding of personalized surveillance, treatment options across genetic subtypes, and quality of life during treatment.